Will regulatory issues continue to be a major barrier to access to bedaquiline and delamanid?

Eur Respir J. 2018 Mar 22;51(3):1702480. doi: 10.1183/13993003.02480-2017. Print 2018 Mar.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antitubercular Agents / administration & dosage*
  • Diarylquinolines / administration & dosage*
  • Diffusion of Innovation
  • Drug Approval
  • Drug and Narcotic Control
  • Global Health
  • Health Services Accessibility*
  • Humans
  • Nitroimidazoles / administration & dosage*
  • Oxazoles / administration & dosage*
  • Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

  • Antitubercular Agents
  • Diarylquinolines
  • Nitroimidazoles
  • OPC-67683
  • Oxazoles
  • bedaquiline